ifosfamide has been researched along with Diffuse Parenchymal Lung Disease in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC." | 2.71 | Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YM | 1 |
| Shih, JF | 1 |
| Lee, CS | 1 |
| Chen, MC | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Perng, RP | 1 |
1 trial available for ifosfamide and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2003 |